Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Barbara Burtness, Jean P Bourhis, Jan B Vermorken, Kevin J Harrington, Ezra EW Cohen

ABSTRACT

BACKGROUND: Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement, non-oropharynx primary sites, human papillomavirus (HPV)-negative oropharyngeal cancer, or HPV-positive oropharynx cancer with smoking history (>10-pack-years). Non-surgical approaches include concurrent chemoradiotherapy, induction chemotherapy followed by definitive radiotherapy or chemoradiotherapy, or radiotherapy alone. Following locoregional therapies (including surgical salvage of residual cervical nodes), no standard intervention exists. Overexpression of epidermal growth factor receptor (EGFR), an ErbB family member, is associated with poor prognosis in HNSCC. EGFR-targeted cetuximab is the only targeted therapy that impacts overall survival and is approved for HNSCC in the USA or Europe. However, resistance often occurs, and new approaches, such as targeting multiple ErbB family members, may be required. Afatinib, an irreversible ErbB family blocker, demonstrated antiproliferative activity in preclinical models and comparable clinical efficacy with cetuximab in a randomized phase II trial in recurrent or metastatic HNSCC. LUX-Head & Neck 2, a phase III study, will assess adjuvant afatinib versus placebo following chemoradiotherapy in primary unresected locoregionally advanced intermediate-to-high-risk HNSCC. METHODS/DESIGN: Patients with primary unresected locoregionally advanced HNSCC, in good clinical condition with unfavourable risk of recurrence, and no evidence of disease after chemoradiotherapy will be randomized 2:1 to oral once-daily afatinib (40 mg starting dose) or placebo. As HPV status will not be determined for eligibility, unfavourable risk is defined as non-oropharynx primary site or oropharynx cancer in patients with a smoking history (>10 pack-years). Treatment will continue for 18 months or until recurrence or unacceptable adverse events occur. The primary endpoint measure is duration of disease-free survival; secondary endpoint measures are disease-free survival rate at 2 years, overall survival, health-related quality of life and safety. DISCUSSION: Given the unmet need in the adjuvant treatment of intermediate-to-high-risk HNSCC patients, it is expected that LUX-Head & Neck 2 will provide new insights into treatment in this setting and might demonstrate the ability of afatinib to significantly improve disease-free survival, compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov NCT01345669. More... »

PAGES

469

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1745-6215-15-469

DOI

http://dx.doi.org/10.1186/1745-6215-15-469

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047546508

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25432788


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Afatinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Squamous Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemoradiotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Head and Neck Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Squamous Cell Carcinoma of Head and Neck", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale University School of Medicine, 333 Cedar Street, 06520, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burtness", 
        "givenName": "Barbara", 
        "id": "sg:person.01142756570.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142756570.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital of Lausanne", 
          "id": "https://www.grid.ac/institutes/grid.8515.9", 
          "name": [
            "Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bourhis", 
        "givenName": "Jean P", 
        "id": "sg:person.014212727502.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014212727502.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antwerp University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411414.5", 
          "name": [
            "Antwerp University Hospital, Edegem, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vermorken", 
        "givenName": "Jan B", 
        "id": "sg:person.0653351227.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653351227.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "Head and Neck Unit, The Royal Marsden Hospital, London, UK", 
            "Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harrington", 
        "givenName": "Kevin J", 
        "id": "sg:person.01167312032.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167312032.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Diego", 
          "id": "https://www.grid.ac/institutes/grid.266100.3", 
          "name": [
            "University of California San Diego Moores Cancer Center, La Jolla, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Ezra EW", 
        "id": "sg:person.013135111462.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013135111462.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/mdu216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001585170"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001585170"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa053422", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005630380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.49.8782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005875032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.49.8782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005875032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(12)70086-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007000373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/era.13.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008410941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0912217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009375074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1055-9965.epi-10-1262", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010325861"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0360-3016(92)90642-u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013929853"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00066-007-1696-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014186766", 
          "https://doi.org/10.1007/s00066-007-1696-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/jpet.112.197756", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017522498"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra001375", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018740792"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)60728-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019242179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(95)00124-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022930194"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023017475", 
          "https://doi.org/10.1038/bjc.1990.175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1990.175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023017475", 
          "https://doi.org/10.1038/bjc.1990.175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2008.109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025699363", 
          "https://doi.org/10.1038/onc.2008.109"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-14-473", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026757724", 
          "https://doi.org/10.1186/1471-2407-14-473"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-14-473", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026757724", 
          "https://doi.org/10.1186/1471-2407-14-473"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-0784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026807381"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0802656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031603011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.thorsurg.2014.12.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032347522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.9.709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032742623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(07)71225-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034819847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-2040", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037331266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-2040", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037331266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.gene.2005.10.018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038589426"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038771217", 
          "https://doi.org/10.1038/sj.bjc.6604108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.29.2904", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039986802"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2008.19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041120299", 
          "https://doi.org/10.1038/onc.2008.19"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1055-9965.epi-04-0551", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043528482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semradonc.2012.03.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044026835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncponc0750", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045094910", 
          "https://doi.org/10.1038/ncponc0750"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-012-0159-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045717066", 
          "https://doi.org/10.1007/s12032-012-0159-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-012-0159-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045717066", 
          "https://doi.org/10.1007/s12032-012-0159-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.12.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046073612"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-012-9904-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048880150", 
          "https://doi.org/10.1007/s10637-012-9904-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.02.4646", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049107817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10555-005-5047-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051740177", 
          "https://doi.org/10.1007/s10555-005-5047-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10555-005-5047-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051740177", 
          "https://doi.org/10.1007/s10555-005-5047-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2009.04.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053500952"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/era.13.31", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053724462"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075208266", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.5.838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078438170"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu438.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083557950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.32.15_suppl.8004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111107290"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "BACKGROUND: Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement, non-oropharynx primary sites, human papillomavirus (HPV)-negative oropharyngeal cancer, or HPV-positive oropharynx cancer with smoking history (>10-pack-years). Non-surgical approaches include concurrent chemoradiotherapy, induction chemotherapy followed by definitive radiotherapy or chemoradiotherapy, or radiotherapy alone. Following locoregional therapies (including surgical salvage of residual cervical nodes), no standard intervention exists. Overexpression of epidermal growth factor receptor (EGFR), an ErbB family member, is associated with poor prognosis in HNSCC. EGFR-targeted cetuximab is the only targeted therapy that impacts overall survival and is approved for HNSCC in the USA or Europe. However, resistance often occurs, and new approaches, such as targeting multiple ErbB family members, may be required. Afatinib, an irreversible ErbB family blocker, demonstrated antiproliferative activity in preclinical models and comparable clinical efficacy with cetuximab in a randomized phase II trial in recurrent or metastatic HNSCC. LUX-Head & Neck 2, a phase III study, will assess adjuvant afatinib versus placebo following chemoradiotherapy in primary unresected locoregionally advanced intermediate-to-high-risk HNSCC.\nMETHODS/DESIGN: Patients with primary unresected locoregionally advanced HNSCC, in good clinical condition with unfavourable risk of recurrence, and no evidence of disease after chemoradiotherapy will be randomized 2:1 to oral once-daily afatinib (40 mg starting dose) or placebo. As HPV status will not be determined for eligibility, unfavourable risk is defined as non-oropharynx primary site or oropharynx cancer in patients with a smoking history (>10 pack-years). Treatment will continue for 18 months or until recurrence or unacceptable adverse events occur. The primary endpoint measure is duration of disease-free survival; secondary endpoint measures are disease-free survival rate at 2 years, overall survival, health-related quality of life and safety.\nDISCUSSION: Given the unmet need in the adjuvant treatment of intermediate-to-high-risk HNSCC patients, it is expected that LUX-Head & Neck 2 will provide new insights into treatment in this setting and might demonstrate the ability of afatinib to significantly improve disease-free survival, compared with placebo.\nTRIAL REGISTRATION: ClinicalTrials.gov NCT01345669.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1745-6215-15-469", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial", 
    "pagination": "469", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e27f71e0a4d4f319d1fa74ebc6e02142905af7e59bc0ebcff5a8dbe5eaa90704"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25432788"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101263253"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1745-6215-15-469"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047546508"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1745-6215-15-469", 
      "https://app.dimensions.ai/details/publication/pub.1047546508"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99812_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1745-6215-15-469"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-469'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-469'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-469'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-469'


 

This table displays all metadata directly associated to this object as RDF triples.

330 TRIPLES      21 PREDICATES      92 URIs      43 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1745-6215-15-469 schema:about N00a308f07bbc4fc0999a1b1cf2c64952
2 N025da01895b34e62bd7fb0848836954f
3 N0447a32397b24a98835b182d9e7125d0
4 N052e1659de104891a9ffeeba638c7a1e
5 N0798d51547db49ba8883742d621913d1
6 N085e9db8210d43c18cc3b6c03eaccfbd
7 N23e5fa118ac84ced9170514acebeaf8a
8 N30daea1d1d64403a8e5701199cd7aa2e
9 N33a5fa1580b146fe953c0c195c40f09a
10 N3fab9722c9b140d8a0e531fc3e9db5ed
11 N4031868a91644e8fb1302af23e165711
12 N55f14bfc5e9c4e4692da6af28fb7c5fe
13 N58315b1922244789b39168dd16c21e31
14 N5dd2ced18eea41648458493081f8a71f
15 N5f9e14a952464e0da8f16c54f6ce1e5c
16 N80861b0675e64ab994349d37b2a2de64
17 N9e099790f2cb400db0a5422718f682e8
18 Nb914c57ee7354fe789972d4e90ed2d95
19 Nd64156b1bd774b028a6340d9efda4074
20 Nd7896d0bba1b473f989ef631c93268f7
21 Ne180384cf8c242f8aecd4f11111dc25e
22 Nf66b08a8a04c4fca8766da6bf36b5cdf
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author N0e63bb8fdc6749f68ce15ae5f8590c4f
26 schema:citation sg:pub.10.1007/s00066-007-1696-z
27 sg:pub.10.1007/s10555-005-5047-1
28 sg:pub.10.1007/s10637-012-9904-9
29 sg:pub.10.1007/s12032-012-0159-2
30 sg:pub.10.1038/bjc.1990.175
31 sg:pub.10.1038/ncponc0750
32 sg:pub.10.1038/onc.2008.109
33 sg:pub.10.1038/onc.2008.19
34 sg:pub.10.1038/sj.bjc.6604108
35 sg:pub.10.1186/1471-2407-14-473
36 https://app.dimensions.ai/details/publication/pub.1075208266
37 https://doi.org/10.1016/0360-3016(92)90642-u
38 https://doi.org/10.1016/0959-8049(95)00124-2
39 https://doi.org/10.1016/j.gene.2005.10.018
40 https://doi.org/10.1016/j.radonc.2009.04.014
41 https://doi.org/10.1016/j.semradonc.2012.03.003
42 https://doi.org/10.1016/j.thorsurg.2014.12.003
43 https://doi.org/10.1016/s0140-6736(08)60728-x
44 https://doi.org/10.1016/s1359-6349(07)71225-9
45 https://doi.org/10.1016/s1470-2045(12)70086-4
46 https://doi.org/10.1056/nejmoa053422
47 https://doi.org/10.1056/nejmoa0802656
48 https://doi.org/10.1056/nejmoa0912217
49 https://doi.org/10.1056/nejmra001375
50 https://doi.org/10.1093/annonc/mdu216
51 https://doi.org/10.1093/annonc/mdu438.30
52 https://doi.org/10.1093/jnci/92.9.709
53 https://doi.org/10.1124/jpet.112.197756
54 https://doi.org/10.1158/1055-9965.epi-04-0551
55 https://doi.org/10.1158/1055-9965.epi-10-1262
56 https://doi.org/10.1158/1078-0432.ccr-09-0784
57 https://doi.org/10.1158/1078-0432.ccr-10-2040
58 https://doi.org/10.1200/jco.1990.8.5.838
59 https://doi.org/10.1200/jco.2004.12.012
60 https://doi.org/10.1200/jco.2005.02.4646
61 https://doi.org/10.1200/jco.2010.29.2904
62 https://doi.org/10.1200/jco.2012.44.2806
63 https://doi.org/10.1200/jco.2013.49.8782
64 https://doi.org/10.1200/jco.2014.32.15_suppl.8004
65 https://doi.org/10.1586/era.13.30
66 https://doi.org/10.1586/era.13.31
67 schema:datePublished 2014-12
68 schema:datePublishedReg 2014-12-01
69 schema:description BACKGROUND: Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement, non-oropharynx primary sites, human papillomavirus (HPV)-negative oropharyngeal cancer, or HPV-positive oropharynx cancer with smoking history (>10-pack-years). Non-surgical approaches include concurrent chemoradiotherapy, induction chemotherapy followed by definitive radiotherapy or chemoradiotherapy, or radiotherapy alone. Following locoregional therapies (including surgical salvage of residual cervical nodes), no standard intervention exists. Overexpression of epidermal growth factor receptor (EGFR), an ErbB family member, is associated with poor prognosis in HNSCC. EGFR-targeted cetuximab is the only targeted therapy that impacts overall survival and is approved for HNSCC in the USA or Europe. However, resistance often occurs, and new approaches, such as targeting multiple ErbB family members, may be required. Afatinib, an irreversible ErbB family blocker, demonstrated antiproliferative activity in preclinical models and comparable clinical efficacy with cetuximab in a randomized phase II trial in recurrent or metastatic HNSCC. LUX-Head & Neck 2, a phase III study, will assess adjuvant afatinib versus placebo following chemoradiotherapy in primary unresected locoregionally advanced intermediate-to-high-risk HNSCC. METHODS/DESIGN: Patients with primary unresected locoregionally advanced HNSCC, in good clinical condition with unfavourable risk of recurrence, and no evidence of disease after chemoradiotherapy will be randomized 2:1 to oral once-daily afatinib (40 mg starting dose) or placebo. As HPV status will not be determined for eligibility, unfavourable risk is defined as non-oropharynx primary site or oropharynx cancer in patients with a smoking history (>10 pack-years). Treatment will continue for 18 months or until recurrence or unacceptable adverse events occur. The primary endpoint measure is duration of disease-free survival; secondary endpoint measures are disease-free survival rate at 2 years, overall survival, health-related quality of life and safety. DISCUSSION: Given the unmet need in the adjuvant treatment of intermediate-to-high-risk HNSCC patients, it is expected that LUX-Head & Neck 2 will provide new insights into treatment in this setting and might demonstrate the ability of afatinib to significantly improve disease-free survival, compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov NCT01345669.
70 schema:genre research_article
71 schema:inLanguage en
72 schema:isAccessibleForFree true
73 schema:isPartOf N6da9920618874203b5bf0b8f3c0490c3
74 Nb2c56bcb747c4f0593a78f9fadf8ab73
75 sg:journal.1297400
76 schema:name Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
77 schema:pagination 469
78 schema:productId N0f18000b072e4b828b1939c9a843005c
79 N396de4a11df2416ea928ed539de4fd6e
80 N3ee4df9e01294394bca81fad3cf081f4
81 Nbfe1ed3260cc457c87b2fd9c13cc66dd
82 Ne251a14613ab4396aa43ddb6b933567e
83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047546508
84 https://doi.org/10.1186/1745-6215-15-469
85 schema:sdDatePublished 2019-04-11T09:33
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher N85759601682f46a596c74b0823e52e2d
88 schema:url http://link.springer.com/10.1186%2F1745-6215-15-469
89 sgo:license sg:explorer/license/
90 sgo:sdDataset articles
91 rdf:type schema:ScholarlyArticle
92 N00a308f07bbc4fc0999a1b1cf2c64952 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Protein Kinase Inhibitors
94 rdf:type schema:DefinedTerm
95 N025da01895b34e62bd7fb0848836954f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Neoplasm Recurrence, Local
97 rdf:type schema:DefinedTerm
98 N0447a32397b24a98835b182d9e7125d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Chemotherapy, Adjuvant
100 rdf:type schema:DefinedTerm
101 N052e1659de104891a9ffeeba638c7a1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Squamous Cell Carcinoma of Head and Neck
103 rdf:type schema:DefinedTerm
104 N0798d51547db49ba8883742d621913d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Carcinoma, Squamous Cell
106 rdf:type schema:DefinedTerm
107 N085e9db8210d43c18cc3b6c03eaccfbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Neoplasm Staging
109 rdf:type schema:DefinedTerm
110 N0e63bb8fdc6749f68ce15ae5f8590c4f rdf:first sg:person.01142756570.25
111 rdf:rest N168904fc07e0427eb41ec4c311919a94
112 N0f18000b072e4b828b1939c9a843005c schema:name pubmed_id
113 schema:value 25432788
114 rdf:type schema:PropertyValue
115 N168904fc07e0427eb41ec4c311919a94 rdf:first sg:person.014212727502.71
116 rdf:rest N89fc0e84a0ed4533aa7108496b9e4be4
117 N23e5fa118ac84ced9170514acebeaf8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name ErbB Receptors
119 rdf:type schema:DefinedTerm
120 N30daea1d1d64403a8e5701199cd7aa2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Quinazolines
122 rdf:type schema:DefinedTerm
123 N33a5fa1580b146fe953c0c195c40f09a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Clinical Protocols
125 rdf:type schema:DefinedTerm
126 N396de4a11df2416ea928ed539de4fd6e schema:name doi
127 schema:value 10.1186/1745-6215-15-469
128 rdf:type schema:PropertyValue
129 N3ee4df9e01294394bca81fad3cf081f4 schema:name nlm_unique_id
130 schema:value 101263253
131 rdf:type schema:PropertyValue
132 N3fab9722c9b140d8a0e531fc3e9db5ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Molecular Targeted Therapy
134 rdf:type schema:DefinedTerm
135 N4031868a91644e8fb1302af23e165711 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Time Factors
137 rdf:type schema:DefinedTerm
138 N4ba8a4a6c6c44922b9dd6e990a567bb5 rdf:first sg:person.01167312032.35
139 rdf:rest Nea7cb4c057fd4c57b4280bc46cc5fc5d
140 N55f14bfc5e9c4e4692da6af28fb7c5fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Disease-Free Survival
142 rdf:type schema:DefinedTerm
143 N58315b1922244789b39168dd16c21e31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 N5dd2ced18eea41648458493081f8a71f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Head and Neck Neoplasms
148 rdf:type schema:DefinedTerm
149 N5f9e14a952464e0da8f16c54f6ce1e5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Double-Blind Method
151 rdf:type schema:DefinedTerm
152 N6da9920618874203b5bf0b8f3c0490c3 schema:volumeNumber 15
153 rdf:type schema:PublicationVolume
154 N80861b0675e64ab994349d37b2a2de64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Quality of Life
156 rdf:type schema:DefinedTerm
157 N85759601682f46a596c74b0823e52e2d schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 N89fc0e84a0ed4533aa7108496b9e4be4 rdf:first sg:person.0653351227.67
160 rdf:rest N4ba8a4a6c6c44922b9dd6e990a567bb5
161 N9e099790f2cb400db0a5422718f682e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Afatinib
163 rdf:type schema:DefinedTerm
164 Nb2c56bcb747c4f0593a78f9fadf8ab73 schema:issueNumber 1
165 rdf:type schema:PublicationIssue
166 Nb914c57ee7354fe789972d4e90ed2d95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Research Design
168 rdf:type schema:DefinedTerm
169 Nbfe1ed3260cc457c87b2fd9c13cc66dd schema:name readcube_id
170 schema:value e27f71e0a4d4f319d1fa74ebc6e02142905af7e59bc0ebcff5a8dbe5eaa90704
171 rdf:type schema:PropertyValue
172 Nd64156b1bd774b028a6340d9efda4074 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Treatment Outcome
174 rdf:type schema:DefinedTerm
175 Nd7896d0bba1b473f989ef631c93268f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Antineoplastic Agents
177 rdf:type schema:DefinedTerm
178 Ne180384cf8c242f8aecd4f11111dc25e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Risk Factors
180 rdf:type schema:DefinedTerm
181 Ne251a14613ab4396aa43ddb6b933567e schema:name dimensions_id
182 schema:value pub.1047546508
183 rdf:type schema:PropertyValue
184 Nea7cb4c057fd4c57b4280bc46cc5fc5d rdf:first sg:person.013135111462.33
185 rdf:rest rdf:nil
186 Nf66b08a8a04c4fca8766da6bf36b5cdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Chemoradiotherapy
188 rdf:type schema:DefinedTerm
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
193 schema:name Oncology and Carcinogenesis
194 rdf:type schema:DefinedTerm
195 sg:journal.1297400 schema:issn 1468-6708
196 1745-6215
197 schema:name Trials
198 rdf:type schema:Periodical
199 sg:person.01142756570.25 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
200 schema:familyName Burtness
201 schema:givenName Barbara
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142756570.25
203 rdf:type schema:Person
204 sg:person.01167312032.35 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
205 schema:familyName Harrington
206 schema:givenName Kevin J
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167312032.35
208 rdf:type schema:Person
209 sg:person.013135111462.33 schema:affiliation https://www.grid.ac/institutes/grid.266100.3
210 schema:familyName Cohen
211 schema:givenName Ezra EW
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013135111462.33
213 rdf:type schema:Person
214 sg:person.014212727502.71 schema:affiliation https://www.grid.ac/institutes/grid.8515.9
215 schema:familyName Bourhis
216 schema:givenName Jean P
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014212727502.71
218 rdf:type schema:Person
219 sg:person.0653351227.67 schema:affiliation https://www.grid.ac/institutes/grid.411414.5
220 schema:familyName Vermorken
221 schema:givenName Jan B
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653351227.67
223 rdf:type schema:Person
224 sg:pub.10.1007/s00066-007-1696-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1014186766
225 https://doi.org/10.1007/s00066-007-1696-z
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s10555-005-5047-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051740177
228 https://doi.org/10.1007/s10555-005-5047-1
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s10637-012-9904-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048880150
231 https://doi.org/10.1007/s10637-012-9904-9
232 rdf:type schema:CreativeWork
233 sg:pub.10.1007/s12032-012-0159-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045717066
234 https://doi.org/10.1007/s12032-012-0159-2
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/bjc.1990.175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023017475
237 https://doi.org/10.1038/bjc.1990.175
238 rdf:type schema:CreativeWork
239 sg:pub.10.1038/ncponc0750 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045094910
240 https://doi.org/10.1038/ncponc0750
241 rdf:type schema:CreativeWork
242 sg:pub.10.1038/onc.2008.109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025699363
243 https://doi.org/10.1038/onc.2008.109
244 rdf:type schema:CreativeWork
245 sg:pub.10.1038/onc.2008.19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041120299
246 https://doi.org/10.1038/onc.2008.19
247 rdf:type schema:CreativeWork
248 sg:pub.10.1038/sj.bjc.6604108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038771217
249 https://doi.org/10.1038/sj.bjc.6604108
250 rdf:type schema:CreativeWork
251 sg:pub.10.1186/1471-2407-14-473 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026757724
252 https://doi.org/10.1186/1471-2407-14-473
253 rdf:type schema:CreativeWork
254 https://app.dimensions.ai/details/publication/pub.1075208266 schema:CreativeWork
255 https://doi.org/10.1016/0360-3016(92)90642-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1013929853
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1016/0959-8049(95)00124-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022930194
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1016/j.gene.2005.10.018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038589426
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1016/j.radonc.2009.04.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053500952
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1016/j.semradonc.2012.03.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044026835
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/j.thorsurg.2014.12.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032347522
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/s0140-6736(08)60728-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019242179
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1016/s1359-6349(07)71225-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034819847
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1016/s1470-2045(12)70086-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007000373
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1056/nejmoa053422 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005630380
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1056/nejmoa0802656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031603011
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1056/nejmoa0912217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009375074
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1056/nejmra001375 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018740792
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1093/annonc/mdu216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001585170
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1093/annonc/mdu438.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083557950
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1093/jnci/92.9.709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032742623
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1124/jpet.112.197756 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017522498
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1158/1055-9965.epi-04-0551 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043528482
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1158/1055-9965.epi-10-1262 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010325861
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1158/1078-0432.ccr-09-0784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026807381
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1158/1078-0432.ccr-10-2040 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037331266
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1200/jco.1990.8.5.838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078438170
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1200/jco.2004.12.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046073612
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1200/jco.2005.02.4646 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049107817
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1200/jco.2010.29.2904 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039986802
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1200/jco.2012.44.2806 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022055849
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1200/jco.2013.49.8782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005875032
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1200/jco.2014.32.15_suppl.8004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111107290
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1586/era.13.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008410941
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1586/era.13.31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053724462
314 rdf:type schema:CreativeWork
315 https://www.grid.ac/institutes/grid.18886.3f schema:alternateName Institute of Cancer Research
316 schema:name Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK
317 Head and Neck Unit, The Royal Marsden Hospital, London, UK
318 rdf:type schema:Organization
319 https://www.grid.ac/institutes/grid.266100.3 schema:alternateName University of California, San Diego
320 schema:name University of California San Diego Moores Cancer Center, La Jolla, CA, USA
321 rdf:type schema:Organization
322 https://www.grid.ac/institutes/grid.411414.5 schema:alternateName Antwerp University Hospital
323 schema:name Antwerp University Hospital, Edegem, Belgium
324 rdf:type schema:Organization
325 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
326 schema:name Yale University School of Medicine, 333 Cedar Street, 06520, New Haven, CT, USA
327 rdf:type schema:Organization
328 https://www.grid.ac/institutes/grid.8515.9 schema:alternateName University Hospital of Lausanne
329 schema:name Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
330 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...